Background: Vertebral fracture, one of the most frequent osteoporotic fractures in both sexes, is a powerful indicator of future osteoporotic fractures. Vertebral fractures are associated with increased mortality and decreased quality of life. Osteoporosis is a major predictor of low-trauma fracture. The Male Osteoporosis Risk Estimation Score (MORES), a clinical prediction tool that uses age, weight, and a history of chronic obstructive pulmonary disorder, was developed and validated previously to identify men at risk for hip osteoporosis who might benefit from bone densitometry. This study evaluated the effectiveness of the MORES to identify men at risk of lumbar osteoporosis.
The prevalence of osteoporosis in men is expected to increase by nearly 50% during the next 15 years. 1 Worldwide, hip fracture rates are expected to double by 2025, with a disproportionate increase in men. 2 Osteoporosis is a major predictor of future fractures; therefore, the need to understand risk factors for osteoporosis and osteoporotic fractures in men deserves immediate attention. 3 We previously reported on the development and initial validation of the Male Osteoporosis Risk Estimation Score (MORES), 4 a clinical instrument that effectively identified men at increased risk of osteoporosis of the hip; however, the ability to predict vertebral osteoporosis was not addressed. Vertebral fractures are the most common osteoporotic fracture found in men and women 5, 6 and are a strong predictor of future osteoporotic fractures. [7] [8] [9] [10] [11] Like hip fractures, vertebral osteoporotic fractures are associated with significant mortality and morbidity. [12] [13] [14] [15] Vertebral fractures in men have been associated with decreased survival when compared with men who do not fracture, and with greater mortality risk when compared with women with vertebral fractures. 15 Vertebral fractures, and the resultant increase in mortality and morbidity, are not inevitable. Estimates of reduction in fracture risk for men who re-ceive treatment for osteoporosis are similar to those achieved by women receiving treatment. 16 -22 In addition, based on a recent meta-analysis, treatment of osteoporosis with alendronate produced a greater reduction of risk for vertebral fractures (0.52) than the risk reduction observed with treatment of osteoporosis of the hip (0.63). 20 Compounding the expected increase in osteoporotic fractures are reports indicating that osteoporosis among men is still substantially underdiagnosed, undertreated, and inadequately researched. 1, 23 In 2007 the International Society for Clinical Densitometry addressed the underdiagnosis issue with a recommendation for universal bone mineral density (BMD) screening for men 70 years of age and older. 24, 25 In 2008, the National Osteoporosis Foundation included men in their screening recommendations, advocating BMD testing for men 50 to 70 years of age who have one or more risk factors for osteoporosis and BMD testing of men at age Ն70 years without risk factors. 26 These recommendations emphasize the importance of screening but they lack specificity and therefore may not be applied uniformly or efficiently in clinical practice.
Recently published studies have identified specific risk factors for osteoporosis in men. The Osteoporosis Fractures in Men (MrOS), a large observational study, found that factors such as age, race, height, change in height, personal and family history of fracture, diagnoses of chronic obstructive pulmonary disorder (COPD) or kidney stones, and the use of selective serotonin reuptake inhibitors predicted BMD. 27 However, MrOS did not address application of the findings in a clinical setting. In a systematic review Espallargues and colleagues 28 stratified an extensive list of risk factors into 3 categories: high risk for fracture, moderate risk for fracture, and no risk or protective fracture. They suggest that these factors can be used to guide BMD testing decisions. More recently, the MORES used age, low body weight (Ͻ70 kg), and a history of COPD to effectively identify men with an increased risk of osteoporosis of the hip. 4 The MORES is a simple instrument that can be readily applied in the clinical encounter to select men for screening for osteoporosis of the hip; however, the MORES has not been evaluated for identifying osteoporosis of the lumbar spine.
The primary objective of this study was to evaluate the clinical performance of the MORES to identify men at risk for lumbar osteoporosis and to assess the effectiveness of screening men for lumbar osteoporosis. In addition, we conducted a stratified analysis of effectiveness across 3 ethnic groups. 29 The DXA scans were done using a Hologic QDR-4500A fan beam densitometer (Hologic, Inc., Bedford, Massachusetts). Hologic software version 8.26:a3* was used to administer all scans.
Methods

Subjects
Men were excluded from DXA examination because of self-reported history of radiographic contrast material (barium) use during the previous 7 days, self-reported nuclear medicine studies during the previous 3 days, and self-reported weight more than 300 pounds or height more than 6Ј5" (DXA table limitations). 30 The study protocol was approved by the Institutional Review Board of the University of Texas Medical Branch.
Data and Variables
Inclusion criteria were male sex and age of Ն50 years with a readable DXA. Variables included (1) race/ethnicity (self-identified) of white, black, Mexican-American, or "other" (other Hispanic, other racial groups including a multiracial designation, and those missing a specific response to race) 29 ; (2) measured weight; and (3) the presence of COPD (self-reported emphysema or chronic bronchitis). Age was modeled as an ordinal variable, and the youngest age group served as the reference group. Weight was modeled as an ordinal variable with the heaviest weight being the reference group. History of COPD was modeled as a dichotomous variable based on self-report, and men with no history of COPD served as the reference group. Point assignments for each of these groups were the same as those used in the original validation of the MORES index.
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MORES
The MORES
4 is a clinical prediction rule designed for use in an office setting to select men for DXA screening of the hip. The instrument was developed and validated in the NHANES 1994 to 1998 (NHANES III) and is defined by 3 factors: age, weight, and history of COPD. The MORES is a weighted scale developed from a logistic regression model using gender-neutral risk factors for osteoporosis or osteoporosis-related fracture and was validated using split sample methods. Table 1 lists the variables, scoring system, and threshold values assigned for the MORES. Predictor variables evaluated during development included sociodemographic data (age, weight, race/ethnicity, level of education, and marital status); medical and family history (medical comorbidities, family history of osteoporosis, and maternal history of hip fracture); health-related behaviors (use of alcohol and tobacco and level of physical activity); and self-rated health status. For osteoporosis of the hip, the MORES had an overall sensitivity of 0.93 (95% CI, 0.85-0.97) and a specificity of 0.59 (95% CI, 0.56 -0.62) with an estimated area under the curve (AUC) of 0.832 (95% CI, 0807-0.858). In a number needed to screen (NNS) analysis, the MORES reduced the NNS to prevent one additional hip fracture by approximately 50% across all age groups compared with universal screening. 4 Osteoporosis at each site was defined as a BMD Յ2.5 SD below the mean, using white men 20 to 29 years of age as the reference group, in accordance with the World Health Organization criteria.
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Analysis
Using 2 ϫ 2 contingency tables we estimated the sensitivity and specificity of the MORES using the previously determined cut score of Ն6 for predicting osteoporosis of the lumbar vertebra and for any measured site (thoracic vertebra, lumbar vertebra, arms, ribs, pelvis, or legs). Skull data were not included in this study. AUC for the MORES was also estimated. Analyses were performed using statistical analysis software 9.2 with SUDAAN 9.1.3 (RTI International, Research Triangle Park, NC) to adjust for design effects and weighted sampling. 32, 33 Imputed data provided by NHANES 1999 to 2004 was not included in any of the analyses. To determine the clinical usefulness of the MORES we constructed a table comparing the NNS to prevent one additional vertebral fracture during the next 5 years for successive age categories of men. We constructed the table following the method described by Nelson et al 34 to develop the US Preventive Services Task Force (USPSTF) recommendations for screening for osteoporosis in women. Age-specific prevalence of osteoporosis was derived from the NHANES 1999 to 2004 data. 30 To allow comparison with results of the USPSTF analysis, which used age-group-specific, 5-year fracture rates, we estimated age-specific, 5-year vertebral fracture rates for men from data published by Kanis et al 35 by halving the mean 10-year fracture risk for each 5-year age category. Assumptions for risk reduction with treatment and adherence to treatment were based on the best available information from the medical literature and duplicated the assumptions used by Nelson et al, 34 where appropriate. Formulas for calculation are available by request. Where appropriate, results were reported by race/ethnicity to illustrate the effect of race/ethnicity on the operating characteristics of the MORES.
Results
The study population included a total of 2944 men Ն50 years of age who had an interpretable DXA. Based on self-report, 81% identified themselves as non-Hispanic white; 8.2% as African-American; 3.6% as Mexican-American; and 7.2% as "other" (other Hispanic, other racial groups including a multiracial designation, and those missing a specific response to race). Mean age was 63 years; mean body weight was 86 kg (189 lbs); and prevalence of COPD was 7.7%. The prevalence of osteoporosis in men at any site was 10.3% (95% CI, 9.0 -11.7) and the prevalence of vertebral osteoporosis was 4.3% (95% CI, 3.5-5.4). Results are reported in Table 2 . 30 The prevalence of osteoporosis among African-American men (n ϭ 483) was lower than for other racial/ethnic groups, as reported in Table 3 . 30 The sensitivity for the MORES was 0.655 (95% CI, 0.582-0.721) for identifying men with osteoporosis at any site; the specificity was 0.675 (95% CI, 0.649 -0.701); and AUC was 0.728. When limiting the area of interest to the lumbar spine, the sensitivity for men was 0.582 (95% CI, 0.460 -0.694) and specificity was 0.652 (95% CI, 0.627-0.676); and AUC was 0.657. Complete results stratified by race/ethnicity are reported in Table 4 . We constructed an NNS table to evaluate the impact of the MORES on screening for lumbar osteoporosis. The MORES, when used as a pre-DXA screening tool, consistently reduced the NNS compared with universal screening except in the 85-to 89-year-old age group. For example, the MORES produced NSS in men 50 to 69 years of age (3641-5866) that were similar to the NNS for universal screening in men 70 to 74 years of age (4987), the age recommended for universal screening by the International Society for Clinical Densitometry 24, 25 and the National Osteoporosis Foundation. 26 Full results are reported in Table 5 .
Discussion
In this independent sample of men represented in the NHANES 1999 to 2004 datasets, the MORES proved to be a valid instrument that can be used to identify a subgroup of men at increased risk of osteoporosis at the lumbar spine as well as other combined sites. The operating characteristics of the MORES demonstrated minor differences across racial/ethnic groups. Compared with universal screening, the MORES was able to reduce the NNS to prevent one additional vertebral fracture across all age groups, except in men 85 to 89 years of age. However, the NNS to prevent one additional vertebral fracture using the MORES is greater than the NNS to prevent one additional hip fracture. The magnitude of the NNS to prevent one additional vertebral fracture may not support using the MORES to screen solely for osteoporosis of the lumbar spine. The NNS to prevent one additional fracture at any given site is dependent on a series of complex interactions between the prevalence of osteoporosis, operating characteristics of the MORES, the rate of osteoporotic fractures, and the effectiveness of therapy. Each of these points is addressed because it may have influenced the results observed in this study.
Prevalence
Among men, there is a lower prevalence of DXAdefined osteoporosis at the lumbar vertebra compared with hip. 36 In addition, the prevalence potentially may be affected by concurrent osteoarthrosis. Osteoarthrosis involves hypertrophy of the bone and increases apparent BMD without necessarily increasing strength, an observation also reported by Cauley et al 27 in the MrOS Research Group report and by Orwoll et al. 37 The competing effects of the expected decline in BMD associated with aging and the expected increase in BMD associated with osteoarthrosis over time may lead to misclassification of men with lumbar osteoporosis as "normal," which may render densitometry less reliable for the diagnosis of lumbar osteoporosis. In effect, this misclassification decreases the observed prevalence of osteoporosis and necessarily increases the NNS to prevent one additional vertebral fracture at any given age.
Operating Characteristics
In our previous work 4 we demonstrated that the MORES is an effective and valid instrument that can be used to identify men at risk for osteoporosis of the hip with relatively high sensitivity and moderate specificity. In the current study, we demonstrated that the MORES is a valid instrument that can be used to identify men at risk for osteoporosis of the lumbar spine; however, the observed decrease in sensitivity resulted in poorer discrimination for lumbar osteoporosis compared with hip. (See Table 4 for details.) The potential misclassification of osteoporosis, because of the effect of osteoarthrosis on BMD discussed previously, may influence the operating characteristics of the MORES. For example, the MORES relies heavily on age as a risk factor for osteoporosis. Assuming osteoarthrosis also increases with age, patients who meet the screening threshold on the MORES because of the influence of age may be misclassified as having a "normal" BMD with DXA because of the effect of osteoarthrosis, which would probably result in a loss of sensitivity. Another explanation for the reduced sensitivity of the MORES could be that risk factors other than age, weight, and COPD (used to predict osteoporosis of the hip) may be better predictors of vertebral osteoporosis. In either event, the reduction in sensitivity resulted in an increase in the NNS to prevent one additional vertebral fracture.
Event Rates
In general, we have more specific and more precise data available for osteoporosis of the hip and hip fractures than for vertebral osteoporosis and related fractures. In the original MORES study (hip) we were able to use hip fracture rates given a BMD consistent with osteoporosis, ie, t score less than Ϫ2.5. However, in the current analysis we were unable to find published data with comparable specificity and precision. Therefore, we used the best data available and estimated vertebral fracture rates without respect to BMD or site of fracture (thoracic vs lumbar). This resulted in a lower fracture event rate than one might expect given osteoporosis of the spine and therefore would effectively increase the NNS to prevent one additional vertebral fracture. In addition, age-related fractures of the spine increase at a lesser rate than hip fractures. Therefore, as age increases, fracture rates for the spine have less effect on reducing the NNS to prevent one additional fracture than do fracture rates for the hip.
Effectiveness
The increased effectiveness of treatment resulting in the prevention of vertebral fracture compared with hip fracture should decrease the NNS to prevent one additional vertebral fracture. The relative risk for vertebral fracture with treatment is reported as 0.52 versus the relative risk for hip fracture with treatment of 0.63. 34 However, the opposing effects of the other 3 factors described above seem to override the effectiveness of treatment.
An existent vertebral fracture is a strong predictor for a future fracture at any site, but the predictive value of the vertebral BMD may be of less clinical importance. In addition, although a low vertebral BMD accurately predicts osteoporosis and an increased risk of vertebral fracture, a normal vertebral BMD may not exclude osteoporosis and subsequent risk of fracture because of coexistent osteoarthrosis. Newer modalities, such as the inclu-sion of a vertebral fracture analysis, done at the same time as the bone density measurement, may provide more clinically pertinent information regarding the integrity of the vertebral bodies.
Limitations
Our study had several limitations. First, the lack of reported BMD measurements of the hip in the NHANES 1999 to 2004 datasets prevented validation of the MORES for selecting men with an increased risk of osteoporosis of the hip alone or in combination with the lumbar spine. Simultaneous consideration of BMD measurements of the hip and lumbar spine is the usual approach taken during the clinical encounter. Second, the data related to the probability of experiencing a future vertebral fracture are less specific and less precise than are the data regarding the probability of a future hip fracture. Third, the NNS analysis depended on several assumptions regarding effectiveness of, and adherence to, treatment. Although these assumptions and estimates are derived from clinical trial data and meta-analyses, they may be optimistic when applied to clinical practice, a point noted by Nelson et al 34 in the USPSTF recommendations for women. Finally, the NNS analysis is a surrogate measure for the impact of screening for osteoporosis as opposed to the measurement of hard endpoints such as actual fractures and fracture-related morbidity and mortality.
Future Studies
Further evaluation of the MORES in a clinical setting is warranted to assess the effectiveness of the MORES as a prescreening tool for osteoporosis at the hip alone and combined with osteoporosis of the spine. Validation of the MORES for vertebral osteoporosis, which was the primary focus of this study, proved to be more complex because of the effects of osteoarthrosis on BMD. Vertebral fracture analysis, which is now available on many densitometers, is a promising addition to evaluating the risk of fractures. 38 -40 Vertebral fracture analysis measures height differences between the anterior and posterior segments of each vertebra and may be a better predictor of the risk of vertebral osteoporosis and fracture. Vertebral fracture analysis may overcome misclassification of osteoporosis because of coexistent osteoarthrosis. We plan clinical studies to evaluate the effectiveness of the MORES to identify men at risk for hip and/or vertebral osteoporosis/fracture using a combination of BMD and vertebral fracture analysis.
Finally, studies examining barriers to osteoporosis screening and treatment by clinicians, both in the hospital and ambulatory setting, are also necessary. Ultimately the effectiveness of a clinical prediction rule hinges on changing clinical behavior. Changing clinical behavior is a daunting challenge, which is illustrated by the fact that Ͻ20% of patients receive therapeutic interventions for osteoporosis even after suffering an osteoporotic fracture.
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Conclusion
The current analysis validated the MORES as a clinical tool capable of identifying men at an increased risk for lumbar osteoporosis. Furthermore, the MORES performed similarly across racial/ethnic groups. The MORES did not discriminate as well for lumbar osteoporosis (AUC, 0.657) when compared with osteoporosis of the hip (AUC, 0.832). 4 Compared with universal screening the MORES reduced the NNS to prevent one additional vertebral fracture in all age groups, except in men 85 to 89 years of age. However, the reduction in NNS may be insufficient to support using the MORES to screen solely for osteoporosis of the lumbar spine.
Proven strategies are available to reduce the impact of osteoporosis. Translating these strategies into improved patient outcomes depend on the integration of all levels of health care providers and health care delivery systems. For primary care clinicians, who carry the mantle for comprehensive patient care regardless of setting, it is imperative that we advocate for patients, collaborate with others involved in the care of patients with osteoporosis and osteoporotic fractures, and work in all settings to shift the prevention and treatment of osteoporosis and related fractures from an afterthought to the forefront of care. Future trends in early recognition and treatment of osteoporosis to reduce osteoporotic fractures will be the ultimate measure of our success.
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